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Coincidence of primary myeloﬁbrosis (PMF) and chronic
lymphocytic leukaemia (CLL) in one patient is a rare pheno-
menon. To date, eight cases have been described in the
literature. A 61-year-old woman presented with transfusion-
dependent anaemia in February 2008. Peripheral blood count
showed a normochromic, normocytic anaemia with a haemo-
globin level of 6.0g/dl, and the white blood cell count and
platelets were within the normal range. Differential blood count
revealed leukerythroblastosis, anisocytosis and poikilocytosis,
indicating the presence of myeloﬁbrosis. In addition, atypical
lymphocytes and some Gumprecht’s shadows were present.
Immunophenotyping conﬁrmed the presence of a CD5, CD19
and CD45 positive clone. Bone marrow histology showed a
hypercellular marrow with atypical megakaryopoiesis and a
WHO grade 2 ﬁbrosis (Figure 1), as well as a small lymphocytic
inﬁltrate with the CLL phenotype, accounting for 5% of the
marrow volume (Figure 2). This was consistent with coexistence
of PMF and CLL. Cytogenetic analysis showed a normal
karyotype and molecular analysis revealed no JAK2 mutation.
Ultrasound showed splenomegaly of 17cm at initial presentation.
At the time of diagnosis, CLL was classiﬁed as Binet A.
Anaemia was considered to be secondary to myeloﬁbrosis.
Treatment was started with lenalidomide 5mg/d for 21 days of a
28-day-cycle, because preliminary data showed promising
results for lenalidomide in patients with PMF and CLL. After
2 months of therapy, no severe side effects were observed.
The dose of lenalidomide was then increased to 10mg/d for
21 days of a 28-day-cycle.
At 6 months of therapy, haemoglobin levels increased to
8.5g/dl and the patient became transfusion independent. Spleen
size decreased to 15cm after 3 months of therapy. Differential
blood count was normal at 9 months of treatment. Since
February 2010, lymphocyte counts are within normal range.
After a follow-up period of 35 months, the patient remained
transfusion-independent, with a haemoglobin level of 11.8g/dl.
White blood cell counts and thrombocytes are within normal
range. Leukerythroblastosis, anisocytosis, poikilocytosis and
lymphocytosis did resolve as well, and splenomegaly had
decreased to 13cm. Bone marrow histology showed no sub-
stantial change; ﬁbrosis was still classiﬁed as WHO grade 2, the
marrow was still hypercellular. A lymphocytic inﬁltration could
not be demonstrated at that time. The patient is completely
asymptomatic with an Eastern Cooperative Oncology Group
performance status of 0.
PMF has an overall median survival of 69 months (range 2–11
years).
1 Risk factors are age 465 years, haemoglobin o10g/dl,
WBC 425G/l and circulating blasts 41%. Beside these risk
factors, prognosis of patients with PMF is strongly dependent on
the presence of cytogenetic abnormalities, transfusion depen-
dency and the presence of comorbidities. The only curative
treatment option for patients with PMF is allogeneic stem cell
transplantation.
2 For symptomatic splenomegaly, radiation and
splenectomy may be considered. Drugs used for the treatment of
anaemia include androgens, danazol, corticosteroids, erythro-
poietin-stimulating agents and hydroxyurea.
2 Asymptomatic
patients without severe anaemia or marked splenomegaly are
usually under close observation. Recently, immunomodulating
drugs were used in patients with myeloﬁbrosis. Lenalidomide
was shown to be effective as single agent in two phase II trials,
with an overall response rate of 24% for anaemia, 33% for
splenomegaly and 50% for thrombocytopenia.
3 In two other
trials, the combination of lenalidomide with prednisone led to
ambiguous results. The study conducted by Quintas-Cardama
et al.
4 showed promising results with beneﬁts for anaemia and
splenomegaly. Reduction of ﬁbrosis could be demonstrated.
Mesa et al.
5 demonstrated modest activity with a similar
regimen, but no resolution of ﬁbrosis was demonstrated.
Lenalidomide was also shown to be effective in CLL patients
with relapsed/refractory disease, as well as in chemotherapy
naı ¨ve patients. A phase II study conducted by the Roswell Park
Cancer Institute showed an overall response rate and complete
response rate of 47 and 9%, respectively, in relapsed CLL
patients, including patients with high risk cytogenetics.
6
Previously untreated patients achieved overall response rates
between 47 and 65%.
7 Severe tumour lysis and tumour ﬂare
reactions have been described in patients treated with 25mg/d
of lenalidomide.
Coincidence of PMF and CLL is uncommon in one patient. Up
to now, eight cases have been described in the literature.
8
Median age of these patients (including our patient) was 66
years, with a male preponderance (m:f¼2:1). PMF was the
initial diagnosis in ﬁve patients and was followed by the
manifestation of CLL, with a median time of 44 months. One
patient had initially CLL, and PMF was diagnosed 31 months
later. Two patients had a simultaneous diagnosis of PMF and
CLL. Treatment of these patients was heterogeneous. Three out
of eight patients did not receive any therapy. Two patients
received chlorambucil with or without prednisone, and one
patient was treated with steroids, vincristine and cyclo-
phosphamide. Two patients received supportive therapy with
blood transfusions only. All eight patients were published before
lenalidomide was available. First reports of the efﬁcacy of
lenalidomide in PMF and CLL appeared in 2006.
3,6 Our patient
strictly refused allogeneic stem cell transplantation. On the basis
of the literature, we commenced the patient on lenalidomide
instead. The drug was administered within a named patient
programme, offered by the manufacturing company.
Potential pathomechanisms for the coincidence of a myelo-
proliferative and a lymphoproliferative disease are being
discussed in the literature, but remain unclear.
8 Besides a
random coincidence of two different diseases, a simultaneous
proliferation of two cell lines triggered by a single cause could
serve as an explanation. The proliferation of a lymphocytic and
a myelogenous cell line derived from a common pluripotent
stem cell is favoured as potential pathomechanism by the
majority of authors. The presence of a cytogenetic or molecular
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would support this hypothesis. Until now, a common marker for
PMF and CLL has not been identiﬁed.
The patient in this case vignette was diagnosed with a
myeloproliferative and a lymphoproliferative disease at the
same time. PMF with leukerythroblastosis, splenomegaly and
transfusion-dependent anaemia was clearly the dominant
disease. CLL presented with lymphocytosis, a small bone
marrow inﬁltrate, but no lymphadenopathy. First signs of a
treatment effect were increasing haemoglobin levels and a
decreasing spleen size at 3 months. In contrast, changes in
lymphocytosis were noted after 24 months of therapy. These
ﬁndings let us prefer the hypothesis that both diseases did
emerge randomly in two different cell lines.
In summary, little is known about pathogenetic mechanism,
treatment approaches and prognosis of patients presenting with
coexisting PMF and CLL. As publication of the ﬁrst case in 1957,
eight more cases have been reported in the literature. New
agents like lenalidomide might be an option for some of those
patients. Treatment with lenalidomide is successful in our
patient; she is asymptomatic and does not need any transfusions
or any other speciﬁc therapy since 2008.
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Figure 1 Bone marrow histology Gomori  400: ﬁbrosis.
Figure 2 Bone marrow histology HE  600: lymphocytic inﬁltrate.
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